Surgeons at NYU Langone Health performed the first-ever combined mechanical heart pump and gene-edited pig …
Sunrise Oncology Centre Introduces Comprehensive Cancer Care in Vasai, a First for Palghar District
Sunrise Oncology Centre, a leading provider of comprehensive cancer care, is proud to announce the …
MigraKet® Brings the World’s First Medical Food For Migraine to the U.S
International wellness brand Brain Ritual is launching MigraKet®, a revolutionary approach to migraine management developed by …
Venus Remedies awarded its first incentive of Rs.7.50 cr. under PLI scheme
Venus Remedies Ltd, one of India’s leading manufacturers of generic drugs, has been awarded its …
BioVie’s NE3107 Demonstrates Potential Improvements in Motor and Non-motor Symptoms for Parkinson’s Disease Patients and May Be Realigning Physiological Processes for Alzheimer’s Patients in Data to be Presented at the International Conference on Alzheimer’s and Parkinson’s Diseases 2024
BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies …
Record-making Partnerships: IntraCare Continues to Strengthen Presence in Arizona as Three More Clinics Sign on in December
IntraCare, a prominent Texas-based MSO, gained record growth in the month of December 2023 upon signing partnership agreements …
China Medical University Hospital (CMUH) in Taiwan Upgrades Smart Healthcare with Gen AI
China Medical University Hospital (CMUH) in Taiwan announced its collaboration with Google Cloud in mid-December 2023. Using Google Cloud’s …
New Guidance Published in The Lancet Recommends Early Intervention and Use of BIS to Reduce Impact of Arm Lymphedema on Breast Cancer Patients
ImpediMed, a pioneer in the field of medical technology, announced a significant advancement in the …
Chiesi Global Rare Diseases Announces Health Canada Approval of MYALEPTA™ (metreleptin for injection) for the Treatment of Patients with Lipodystrophy
Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative …
SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 against Mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis Conference
SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat …
